Bellevue Asset Management (Switzerland)’s Myriad Genetics MYGN Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$604K	Sell	14,000 -19,000	-58%	-$803K	0.09%	112
2015 Q3	$1.24M	Sell	33,000 -5,000	-13%	-$177K	0.2%	100
2015 Q2	$1.29M	Buy	38,000 +14,000	+58%	+$476K	0.18%	104
2015 Q1	$850K	Buy	+24,000	New	+$859K	0.12%	121

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s MYGN Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) reduced its Myriad Genetics (MYGN) stake by 58% in Q4 2015, selling an estimated $803K and leaving 14,000 shares worth $604K. The position accounts for 0.09% of the portfolio, ranked #112.

Bellevue Asset Management (Switzerland) first reported a position in MYGN in Q1 2015 and has held it in 4 quarters since. The position peaked at $1.29M in Q2 2015. 233 funds tracked by Wall St. Rank hold MYGN as of Q4 2015.

Bellevue Asset Management (Switzerland) held 14,000 shares of Myriad Genetics worth $604K as of Q4 2015.
Bellevue Asset Management (Switzerland) sold 19,000 Myriad Genetics shares in Q4 2015, an estimated $803K.
Myriad Genetics made up 0.09% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #112 holding.
Bellevue Asset Management (Switzerland) first reported a position in Myriad Genetics in Q1 2015 and has held it in 4 quarters since.
Bellevue Asset Management (Switzerland)'s Myriad Genetics position peaked at $1.29M in Q2 2015.
233 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.